Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Inhalation to Improve Host Defense and Pulmonary Barrier Restoration

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

September 22, 2021

Study Completion Date

July 31, 2022

Conditions
ARDS
Interventions
DRUG

inhaled molgramostim (rhGM-CSF)

DRUG

inhaled placebo

formulated as the active substance without molgramostim

Trial Locations (7)

20246

Universitätsklinikum Hamburg-Eppendorf, Klinik für Intensivmedizin, Hamburg

30625

Medizinische Hochschule Hannover, Klinik für Pneumologie, Hanover

60590

Universitätsklinikum Frankfurt, Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Frankfurt

97080

Klinik und Poliklinik für Anästhesiologie, Intensivmedizin, Notfallmedizin und Schmerztherapie, Würzburg

Unknown

Universities of Marburg and Giessen Lung Center, Giessen

University Hospital Marburg, Department of Anaesthesiology and Intensive Care Medicine, Marburg

07747

Universitätsklinikum Jena, Klinik für Anästhesiologie und Intensivmedizin, Jena

All Listed Sponsors
lead

University of Giessen

OTHER

NCT02595060 - Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Inhalation to Improve Host Defense and Pulmonary Barrier Restoration | Biotech Hunter | Biotech Hunter